Compare RDY & TAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | TAP |
|---|---|---|
| Founded | 1984 | 1873 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.1B |
| IPO Year | N/A | N/A |
| Metric | RDY | TAP |
|---|---|---|
| Price | $13.85 | $49.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 15 |
| Target Price | $16.90 | ★ $51.67 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 01-20-2026 | 02-18-2026 |
| Dividend Yield | 0.53% | ★ 3.88% |
| EPS Growth | ★ 5.58 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $3,848,694,754.00 | ★ $11,214,000,000.00 |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $2.58 | N/A |
| P/E Ratio | $17.93 | ★ N/A |
| Revenue Growth | ★ 11.09 | N/A |
| 52 Week Low | $12.26 | $42.94 |
| 52 Week High | $16.17 | $64.66 |
| Indicator | RDY | TAP |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 57.83 |
| Support Level | $12.95 | $47.36 |
| Resistance Level | $13.85 | $50.70 |
| Average True Range (ATR) | 0.27 | 1.21 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 91.20 | 64.37 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.